J. Michalski

发表

Radiation dose-volume effects in radiation-induced rectal injury.

J. Deasy, S. Tucker, A. Jackson, 2010, International journal of radiation oncology, biology, physics.

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial

D. Low, H. Sandler, G. Rodrigues, 2022, The Lancet.

Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial

J. Galvin, H. Sandler, J. Bahary, 2013 .

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, S. Yeung, 2022, npj Digital Medicine.

Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy

G. Andriole, H. Gay, N. Andruska, 2022, The Journal of urology.

Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups

M. Knopp, L. Shankar, S. Lerner, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lutetium-177 DOTATATE: A Practical Review.

Nicholas G Zaorsky, D. Spratt, B. Baumann, 2022, Practical radiation oncology.

Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).

Christopher U. Jones, A. Kishan, M. Sydes, 2022, European urology.

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial RTOG 0415

J. Deasy, D. Low, H. Sandler, 2019 .

Long‐term follow‐up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel‐associated quality of life

W. Bosch, D. Hamstra, M. Pinkawa, 2020, BJU international.

Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.

H. Gay, N. Andruska, B. Baumann, 2022, Brachytherapy.

Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical Review.

Nicholas G Zaorsky, D. Spratt, B. Baumann, 2022, Practical radiation oncology.

Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy.

V. Arora, J. Picus, J. Christodouleas, 2022, European urology oncology.

Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.

Christopher U. Jones, E. Horwitz, T. Pisansky, 2023, European urology.

Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.

H. Gay, N. Andruska, B. Baumann, 2022, Brachytherapy.

Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men

Christopher U. Jones, A. Kishan, P. Boutros, 2021, JAMA network open.

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

James R. Anderson, D. Rodeberg, D. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children's Oncology Group Study ACNS0331)

J. Michalski, S. Perkins, Yimei Li, 2022, Advances in radiation oncology.

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer

M. Sanda, H. Gay, A. Jani, 2022, European urology open science.

Quality of Life Implications of Dose-Escalated External Beam Radiation for Localized Prostate Cancer: Results of a Prospective Randomized Phase 3 Clinical Trial, NRG/RTOG 0126.

G. Gustafson, H. Sandler, M. Lock, 2022, International journal of radiation oncology, biology, physics.

Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials

R. Socher, James Y. Zou, M. Lungren, 2022, npj Digital Medicine.

High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.

A. Kishan, M. Sydes, D. Dearnaley, 2022, European urology.

Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer.

H. Gay, N. Andruska, B. Baumann, 2021, Clinical genitourinary cancer.

Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP)

I. Kaplan, D. Beyer, H. Sandler, 2020, International Journal of Radiation Oncology*Biology*Physics.

Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.

P. Tran, É. Vigneault, F. Feng, 2022, Journal of Clinical Oncology.

Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx).

D. Beyer, H. Sandler, É. Vigneault, 2021, International journal of radiation oncology, biology, physics.

Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

H. Sandler, R. Dess, R. Valicenti, 2022, Cancer.

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

D. Yan, H. Sandler, M. Lock, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Brachytherapy Boost with Overall Survival for Gleason 9-10 Prostate Cancer: The Impact of Primary versus Secondary Pattern 5.

H. Gay, P. Rossi, B. Baumann, 2023, Brachytherapy.

Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

D. Brachman, C. Catton, H. Sandler, 2018, International Journal of Radiation Oncology*Biology*Physics.

The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation.

J. Tward, C. Olsson, M. Brawer, 2021, International journal of radiation oncology, biology, physics.

ACR Appropriateness Criteria® Staging of Renal Cell Carcinoma: 2022 Update.

Silvia D. Chang, P. Pierorazio, Rajan T. Gupta, 2023, Journal of the American College of Radiology : JACR.

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Christopher U. Jones, R. Hannan, H. Sandler, 2023, European urology.

Feasibility of Same-Day Prostate Fiducial Markers, Perirectal Hydrogel Spacer Placement, and CT/MRI Simulation for External Beam Radiation Therapy for Low and Intermediate-Risk Prostate Cancer.

S. Goddu, J. Efstathiou, W. Bosch, 2021, Practical radiation oncology.

Patient‐reported outcomes after 3‐dimensional conformal, intensity‐modulated, or proton beam radiotherapy for localized prostate cancer

A. Zietman, H. Sandler, B. Yeap, 2013, Cancer.

Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, M. Lock, 2021, International journal of radiation oncology, biology, physics.

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.

D. Beyer, C. Catton, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

G. Andriole, M. Altman, S. Goddu, 2021, Clinical and translational radiation oncology.

The Association of Radiation Dose With Overall Survival for Patients Treated With Prostate Stereotactic Body Radiation Therapy

H. Gay, N. Andruska, B. Baumann, 2023, Cureus.

A comparative study based on image quality and clinical task performance for CT reconstruction algorithms in radiotherapy

Mark A. Anastasio, Sasa Mutic, Daniel A. Low, 2016, Journal of applied clinical medical physics.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

D. Kuban, M. Kattan, C. Roehrborn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.

W. Curran, K. Forster, H. Choy, 2013 .

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

R. Hannan, H. Sandler, J. Purdy, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.

W. Curran, M. Mehta, J. Michalski, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age as an independent prognostic factor in patients with glioblastoma: a radiation therapy oncology group and American College of Surgeons National Cancer Data Base comparison

Luis Souhami, Arnab Chakravarti, Kimberly Porter, 2011, Journal of Neuro-Oncology.

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial

G. Gustafson, D. Yan, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.

J. Eastham, A. Finelli, J. Michalski, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.

M. Kattan, A. Zietman, M. Anscher, 2016, International journal of radiation oncology, biology, physics.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features

A. Niemierko, A. Zietman, M. Anscher, 2018, JAMA oncology.

Development and Implementation of an Open Source Template Interpretation Class Library for Automated Treatment Planning

Geoffrey D. Hugo, F. Reynoso, P. Zygmanski, 2021, Practical Radiation Oncology.

Predicting the outcome of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.

D. Kuban, M. Kattan, C. Roehrborn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, D. Citrin, 2021, International journal of radiation oncology, biology, physics.

A Prospective Phase II Trial of Trans-perineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiotherapy (NRG Oncology/RTOG -0526)

T. Pisansky, N. Pervez, E. Trabulsi, 2019 .